Comparison of propofol-based anesthesia and sevoflurane-based anesthesia on postoperative NK-cell activity and receptor expression after hepatectomy

Comparison of the impact of propofol-based anesthesia and sevoflurane-based anesthesia on N K-cell related immunity during hepatectomy for hepatocellular carcinoma: a pilot study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006189

Enrollment

Registered

2021-05-27

Start date

2021-04-05

Completion date

Unknown

Last updated

2021-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : All study participants will undergo general anesthesia for surgery. Anesthesia is performed using propofol or sevoflurae, depending on the group. Remifentanil is used in both groups. The anesth

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Adults who undergo elective hepatectomy for hepatocellular carcinoma (older than 18 years old and younger than 76 years old) -American society of anesthesia (ASA) class I-III -Patients who have agreed to the trial and signed the subject's consent

Exclusion criteria

Exclusion criteria: - Patients with who have history of side effects from the use of the anesthetic or have contraindication for drugs (a patient suspected of having an allergic reaction to the drug) - Patients who have liver cancer other than hepatocellular carcinoma (eg Cholangiocarcinoma or metastatic liver tumor) - Patients who is deemed inappropriate to participate in the clinical trial by the researcher's judgment - Patients who are allergic to nuts or beans - Patients who have a history of malignant hyperthermia or risk factors of malignant hyperthermia - Patients who underwent interventional procedure for HCC

Design outcomes

Primary

Measure	Time frame
NK-cell activity and receptor expression	—

Secondary

Measure	Time frame
Proinflammatory cytokines, Oxidative stress marker;Immune cell activation marker;pain stimuli ?? ??;cancer cell activity and angiogenesis related marker	—

Countries

Korea, Republic of

Contacts

Public ContactJi-Hye Kwon

Samsung Medical Center

kwonjh0828@hanmail.net+82-2-3410-0369

Outcome results